Kistler-Tiffany Companies’s Sanofi Contingent Value Rights GCVRZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q2
Sell
-79
Closed 653
2020
Q1
$0 Hold
79
﹤0.01% 578
2019
Q4
$0 Hold
79
﹤0.01% 609
2019
Q3
$0 Hold
79
﹤0.01% 615
2019
Q2
$0 Hold
79
﹤0.01% 604
2019
Q1
$0 Hold
79
﹤0.01% 596
2018
Q4
$0 Hold
79
﹤0.01% 599
2018
Q3
$0 Hold
79
﹤0.01% 599
2018
Q2
$0 Hold
79
﹤0.01% 634
2018
Q1
$0 Hold
79
﹤0.01% 611
2017
Q4
$0 Hold
79
﹤0.01% 598
2017
Q3
$0 Hold
79
﹤0.01% 592
2017
Q2
$0 Hold
79
﹤0.01% 552
2017
Q1
$0 Hold
79
﹤0.01% 555
2016
Q4
$0 Hold
79
﹤0.01% 581
2016
Q3
$0 Hold
79
﹤0.01% 770
2016
Q2
$0 Hold
79
﹤0.01% 789
2016
Q1
$0 Hold
79
﹤0.01% 626
2015
Q4
$0 Hold
79
﹤0.01% 660
2015
Q3
$0 Hold
79
﹤0.01% 656
2015
Q2
$0 Hold
79
﹤0.01% 666
2015
Q1
$0 Hold
79
﹤0.01% 652
2014
Q4
$0 Hold
79
﹤0.01% 667
2014
Q3
$0 Hold
79
﹤0.01% 761
2014
Q2
$0 Hold
79
﹤0.01% 725
2014
Q1
$0 Hold
79
﹤0.01% 598
2013
Q4
$0 Hold
79
﹤0.01% 601
2013
Q3
$0 Hold
79
﹤0.01% 623
2013
Q2
$0 Buy
+79
New +$139 ﹤0.01% 605

Kistler-Tiffany Companies's GCVRZ Position: Q2 2020 in Review

Kistler-Tiffany Companies sold out of Sanofi Contingent Value Rights (GCVRZ) in Q2 2020, closing a stake of 79 shares.

Kistler-Tiffany Companies first reported a position in GCVRZ in Q2 2013 and held it in 28 quarters. The position peaked at $0 in Q1 2020. 1 fund tracked by Wall St. Rank holds GCVRZ as of Q2 2020.

  • Kistler-Tiffany Companies reported no remaining Sanofi Contingent Value Rights position as of Q2 2020 after selling out during the quarter.
  • Kistler-Tiffany Companies sold 79 Sanofi Contingent Value Rights shares in Q2 2020.
  • Kistler-Tiffany Companies first reported a position in Sanofi Contingent Value Rights in Q2 2013 and held it in 28 quarters.
  • Kistler-Tiffany Companies's Sanofi Contingent Value Rights position peaked at $0 in Q1 2020.
  • 1 fund tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q2 2020.

Based on Kistler-Tiffany Companies's 13F filing for Q2 2020, filed 20 Jul 2020.